---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-24-001451"
form_type: "8-K"
ticker: "VNRX"
cik: "0000093314"
company_name: "VOLITIONRX LTD"
filed_at: "2024-03-25T23:59:59+00:00"
generated_at: "2026-06-04T08:54:22.785296+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# VolitionRx reports FY2023 revenue up 153% to $775K; cash $20.7M

## Summary
- Revenue of ~$775K in FY2023, up 153% YoY; net cash used in operations $18.1M.
- Cash & equivalents $20.7M at Dec 31, 2023 (vs $10.9M end of 2022); received $13.0M milestone from Heska in Dec 2023.
- Sold kits for over 58,000 Nu.Q Vet Cancer Tests in 2023; new partnerships including Fujifilm Vet Systems; in-house test via Heska/Antech coming soon.
- Nu.Q NETs pillar advanced with FDA regulatory pathway; Capture-PCR breakthrough presented at ESMO 2023.
- Conference call March 26, 2024 at 8:30 AM ET.

## SEC filing metadata
- accession: 0001477932-24-001451
- form_type: 8-K
- ticker: VNRX
- cik: 0000093314
- company_name: VOLITIONRX LTD
- filed_at: 2024-03-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/93314/000147793224001451/0001477932-24-001451-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/93314/000147793224001451/vnrx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-24-001451
- JSON: https://secwatch.observer/filing/0001477932-24-001451.json
- Plain text: https://secwatch.observer/filing/0001477932-24-001451.txt

## Key facts
- Earnings Releases
  VOLITIONRX LTD reported the full fiscal year ended December 31, 2023 results: revenue approximately $775,000.
  - Period: the full fiscal year ended December 31, 2023
  - Revenue: approximately $775,000
  - Result: reported results
  source text: · Cash and cash equivalents as of December 31, 2023, totaled approximately $20.7 million as compared to $10.9 million as of December 31, 2022. · Recorded approximately $775,000 in revenue in 2023, up 153% over the prior year. · Received $13.0 million in milestone payments from Heska Corporation in December 2023. · Net cash used in operating activities
  evidence_url: https://www.sec.gov/Archives/edgar/data/93314/000147793224001451/0001477932-24-001451-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.